Free Newsletter
Clinical platforms zero in on safety
KEM Clinicals is an update of Ariana Pharmas' Knowledge Extraction and Management platform, a decision-support tool for drug researchers. The new version supports clinical development and safety processes.
The update allows users to test hypotheses, and it generates them consistent with data relevant to trial objectives, according to an announcement. The solution uses such features as optimal inclusion/exclusion criteria in protocol design; early adverse event detection and characterization; identification of surrogate endpoints; and design of composite efficacy/safety endpoints.
Separately, TheraDoc has added six clinical and adverse drug event alert packages to its Expert System informatics platform. The alert bundles work with the platform to provide electronic surveillance of patient data from multiple hospital information sources.
- here's the KEM Clinicals release
- see the TheraDocs announcement
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline

SHARE
WITH: